Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Treatment begins with a dose-escalation schedule (0.6 mg weekly increments to 3.0 mg as tolerated) and should be discontinued after 12 weeks at the 3.0 mg dose if at least 5% weight loss has not been achieved
Our batch documentation policy, including how to request the record for a lot you already have, is on the certificate of analysis page
Determine if your current dose is providing a therapeutic benefit
US$ 25.40
US$ 27.54
US$ 24.73
US$ 26.60
US$ 25.01
US$ 20.72
US$ 26.16
US$ 29.56
US$ 21.48
US$ 24.95
US$ 27.94
US$ 26.67
US$ 29.83
US$ 23.29
